Hong Kong (HSI) Healthcare Services Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Healthcare Services Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 01 Jul 2026	HK$133.5b	HK$783.6b	HK$10.7b	13.7x	12.5x	0.2x
Fri, 29 May 2026	HK$148.3b	HK$785.4b	HK$10.7b	13.7x	13.8x	0.2x
Sun, 26 Apr 2026	HK$174.6b	HK$779.5b	HK$10.7b	15.1x	16.4x	0.2x
Tue, 24 Mar 2026	HK$148.3b	HK$767.8b	HK$9.4b	10.4x	15.8x	0.2x
Thu, 19 Feb 2026	HK$162.1b	HK$766.3b	HK$9.3b	11.5x	17.4x	0.2x
Sat, 17 Jan 2026	HK$161.9b	HK$758.3b	HK$9.2b	12.1x	17.6x	0.2x
Mon, 15 Dec 2025	HK$160.5b	HK$744.7b	HK$9.0b	12.3x	17.9x	0.2x
Wed, 12 Nov 2025	HK$179.8b	HK$737.0b	HK$8.9b	12.4x	20.2x	0.2x
Fri, 10 Oct 2025	HK$184.7b	HK$739.8b	HK$8.3b	13.4x	22.3x	0.2x
Sun, 07 Sep 2025	HK$237.0b	HK$823.2b	HK$11.5b	13.1x	20.7x	0.3x
Tue, 05 Aug 2025	HK$225.2b	HK$826.8b	HK$13.0b	13.9x	17.3x	0.3x
Thu, 03 Jul 2025	HK$214.7b	HK$827.0b	HK$13.0b	12.2x	16.5x	0.3x
Sat, 31 May 2025	HK$220.4b	HK$807.8b	HK$10.8b	12.1x	20.5x	0.3x
Mon, 28 Apr 2025	HK$206.3b	HK$796.0b	HK$10.4b	11.1x	19.8x	0.3x
Wed, 26 Mar 2025	HK$191.5b	HK$801.2b	HK$12.0b	12.3x	15.9x	0.2x
Fri, 21 Feb 2025	HK$212.5b	HK$809.2b	HK$14.6b	12.7x	14.6x	0.3x
Sun, 19 Jan 2025	HK$200.1b	HK$802.9b	HK$14.4b	12.4x	13.9x	0.2x
Tue, 17 Dec 2024	HK$224.6b	HK$806.3b	HK$14.5b	12.3x	15.5x	0.3x
Thu, 14 Nov 2024	HK$224.9b	HK$815.0b	HK$14.7b	13.2x	15.3x	0.3x
Sat, 12 Oct 2024	HK$230.2b	HK$830.1b	HK$15.3b	13.8x	15x	0.3x
Mon, 09 Sep 2024	HK$203.7b	HK$838.1b	HK$15.6b	13.2x	13.1x	0.2x
Wed, 07 Aug 2024	HK$231.3b	HK$831.4b	HK$12.7b	10.9x	18.2x	0.3x
Fri, 05 Jul 2024	HK$240.7b	HK$818.2b	HK$12.5b	11x	19.3x	0.3x
Sun, 02 Jun 2024	HK$253.0b	HK$823.0b	HK$12.5b	12.6x	20.2x	0.3x
Tue, 30 Apr 2024	HK$255.2b	HK$821.8b	HK$12.7b	11.9x	20x	0.3x
Thu, 28 Mar 2024	HK$238.1b	HK$822.2b	HK$12.8b	12.2x	18.7x	0.3x
Sat, 24 Feb 2024	HK$248.9b	HK$815.0b	HK$12.0b	14.6x	20.7x	0.3x
Mon, 22 Jan 2024	HK$230.9b	HK$819.5b	HK$12.1b	15.2x	19.1x	0.3x
Wed, 20 Dec 2023	HK$235.5b	HK$818.6b	HK$12.4b	15.4x	18.9x	0.3x
Fri, 17 Nov 2023	HK$257.3b	HK$805.9b	HK$12.1b	13.3x	21.3x	0.3x
Sun, 15 Oct 2023	HK$289.7b	HK$802.6b	HK$12.3b	13.4x	23.5x	0.4x
Tue, 12 Sep 2023	HK$284.8b	HK$804.9b	HK$12.7b	13.1x	22.4x	0.4x
Thu, 10 Aug 2023	HK$290.4b	HK$782.9b	HK$11.5b	9.8x	25.3x	0.4x
Sat, 08 Jul 2023	HK$320.5b	HK$803.3b	-HK$152,178,082.00	11.8x	-2105.9x	0.4x

Current Industry PE

Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.

The industry is trading at a PE ratio of 12.5x which is higher than its 3-year average PE of -68.3x.

The industry is trading close to its 3-year average PS ratio of 0.27x.

Past Earnings Growth

Total earnings for the Healthcare industry have gone up over the last three years, and the industry is now profitable.
Revenues have remained mostly flat. This means that the industry has become more efficient since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	-3.71%
Healthcare	4.97%
Healthcare Services	-1.42%
Managed Healthcare	0%	0
Healthcare Facilities	-0.12%
Healthcare Distributors	-0.86%
Healthcare Services	-3.20%

Industry PE

Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio.

Analysts are expecting annual earnings growth of 35.4%, which is higher than its past year's earnings decline of 30.1% per year.

Investors are most pessimistic about the Healthcare Distributors industry, which is trading below its 3-year average of 12.1x.

Forecasted Growth

Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 35% over the next 5 years.
This is better than its past earnings decline of 30% per year.

In contrast, the Healthcare Distributors industry is expected to see its earnings grow by 9.0% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
1099 Sinopharm Group	HK$15.91	2.1% +HK$998.6m	-13.4%	PE6x
9885 YSB	HK$4.31	29.4% +HK$668.6m	-54.6%	PE16.6x
2651 Wuhan Dazhong Dental Medical	HK$19.00	58.3% +HK$345.7m	n/a	PE28.8x
6078 Hygeia Healthcare Holdings	HK$9.17	3.7% +HK$202.0m	-39.9%	PE29.5x
2677 Distinct Healthcare Holdings	HK$30.02	10.4% +HK$182.1m	n/a	PE12.4x

ADICON Holdings Limited Announces Yeh Richard as the Lead Independent Non-Executive Director, Effective May 27, 2026

ADICON Holdings Limited announced that Mr. YEH Richard, an independent non-executive Director, had been designated as the lead independent non-executive Director with effect from May 27, 2026. Mr. YEH is currently the chairman of the audit committee and a member of the nomination committee of the Board. The responsibilities of the lead independent non-executive Director are not different from or greater than those of other independent non-executive Directors. Mr. YEH’s primary responsibility as the lead independent non-executive Director is to facilitate and strengthen communication among the independent non-executive Directors, between the independent non-executive Directors and the other members of the Board, and with the shareholders (in particular, the minority shareholders). The position of the lead independent non-executive Director is not an executive position in the Company, and the holder of such position does not have any management role in the Group. The designation of the lead independent non-executive Director is introduced with reference to the amended Corporate Governance Code as set out in Appendix C1 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, which became effective on July 1, 2025. As at the date of this announcement, the Board comprised Mr. WANG Legang as an executive Director; Ms. YANG Ling, Mr. LIN Jixun, Mr. LI Bo and Mr. ZHOU Mintao as non-executive Directors; and Mr. MI Brian Zihou, Mr. YEH Richard and Mr. ZHANG Wei as independent non-executive Directors.

Hong Kong (HSI) Healthcare Services Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Genertec Universal Medical Group Company Limited Declares Final Dividend for the Year Ended 31 December 2025

Investor sentiment improves as stock rises 27%

Upcoming dividend of HK$0.042 per share

Now 21% overvalued

Upcoming dividend of HK$0.02 per share

Investor sentiment improves as stock rises 15%

Upcoming dividend of CN¥0.69 per share

New minor risk - Share price stability

ADICON Holdings Limited Announces Yeh Richard as the Lead Independent Non-Executive Director, Effective May 27, 2026

Saint Bella Group Limited, Annual General Meeting, Jun 16, 2026

Chairman & Co-CEO recently bought HK$3.0m worth of stock

Now 23% undervalued

Jiangxi Rimag Group Co., Ltd. Appoints Meng Tao as Non-Executive Director and Member of the Audit Committee, Effective from 23 April 2026

Full year 2025 earnings released: CN¥0.24 loss per share (vs CN¥0.37 loss in FY 2024)